BG60256B1 - Рекомбинантен метод за получаване на лимфотоксин - Google Patents

Рекомбинантен метод за получаване на лимфотоксин

Info

Publication number
BG60256B1
BG60256B1 BG070460A BG7046085A BG60256B1 BG 60256 B1 BG60256 B1 BG 60256B1 BG 070460 A BG070460 A BG 070460A BG 7046085 A BG7046085 A BG 7046085A BG 60256 B1 BG60256 B1 BG 60256B1
Authority
BG
Bulgaria
Prior art keywords
lymphotoxin
new
recombinant method
lymphotoxins
immobilized
Prior art date
Application number
BG070460A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60256B2 (bg
Inventor
Bharat Aggarwal
Timothy BRINGMAN
Patrick Gray
Glenn Nedwin
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG60256B2 publication Critical patent/BG60256B2/bg
Publication of BG60256B1 publication Critical patent/BG60256B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BG070460A 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин BG60256B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09

Publications (2)

Publication Number Publication Date
BG60256B2 BG60256B2 (bg) 1994-03-24
BG60256B1 true BG60256B1 (bg) 1994-03-24

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
BG070460A BG60256B1 (bg) 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин

Country Status (23)

Country Link
EP (2) EP0164965B1 (https=)
JP (3) JP2521703B2 (https=)
AR (1) AR245219A1 (https=)
AT (2) ATE95243T1 (https=)
AU (1) AU599303B2 (https=)
BG (1) BG60256B1 (https=)
CA (1) CA1340641C (https=)
CZ (1) CZ283148B6 (https=)
DE (2) DE3587597T2 (https=)
DK (1) DK171531B1 (https=)
ES (1) ES8802182A1 (https=)
FI (1) FI93025C (https=)
GR (1) GR851317B (https=)
HU (1) HU204085B (https=)
IE (1) IE63487B1 (https=)
IL (1) IL75318A (https=)
NO (1) NO179075C (https=)
NZ (1) NZ212207A (https=)
PL (1) PL155410B1 (https=)
PT (1) PT80573B (https=)
RO (1) RO100383A2 (https=)
SK (1) SK278333B6 (https=)
YU (1) YU47735B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88175C (fi) 1980-04-03 1993-04-13 Biogen Inc Rekombinant-dna-molekyler och foerfaranden foer framstaellning av polypeptider liknande humant -interferon
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0216786B1 (en) * 1984-12-21 1992-03-18 Biogen, Inc. Purification, production and use of tumor necrosis factors
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
EP0230781B1 (en) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin gene, method for its production, and lymphotoxin
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
EP0230574A3 (en) * 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
EP0272894A3 (en) * 1986-12-24 1989-06-14 Takeda Chemical Industries, Ltd. Recombinant human lymphotoxin
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
FI884798A7 (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
JP4231106B2 (ja) * 1995-01-23 2009-02-25 ゼノテック インコーポレイティッド 骨溶解および転移を改善する方法
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6740739B1 (en) 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
EP1572116A4 (en) * 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005067477A2 (en) * 2003-12-08 2005-07-28 Centocor, Inc. Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR20090078349A (ko) * 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3134103B1 (en) * 2014-04-25 2020-01-15 Naurex Inc. Stable compositions of neuroactive peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59007A (en) * 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin

Also Published As

Publication number Publication date
EP0164965B1 (en) 1993-09-29
AR245219A1 (es) 1993-12-30
ES543695A0 (es) 1988-04-16
NO179075B (no) 1996-04-22
JPH07291995A (ja) 1995-11-07
DE3587597T2 (de) 1994-06-01
YU91985A (en) 1988-12-31
ATE95243T1 (de) 1993-10-15
CA1340641C (en) 1999-07-13
HUT37814A (en) 1986-02-28
RO100383B1 (ro) 1991-03-01
SK393085A3 (en) 1996-11-06
PT80573A (en) 1985-06-01
IE63487B1 (en) 1995-05-03
FI93025C (fi) 1995-02-10
ATE195323T1 (de) 2000-08-15
PT80573B (pt) 1987-08-19
JPS6156197A (ja) 1986-03-20
JP2804237B2 (ja) 1998-09-24
DK171531B1 (da) 1996-12-23
DK241385D0 (da) 1985-05-30
DE3587597D1 (de) 1993-11-04
BG60256B2 (bg) 1994-03-24
EP0509553B1 (en) 2000-08-09
HU204085B (en) 1991-11-28
RO100383A2 (ro) 1991-10-17
NZ212207A (en) 1991-07-26
DE3588225D1 (de) 2000-09-14
NO179075C (no) 1996-07-31
CZ283148B6 (cs) 1998-01-14
AU599303B2 (en) 1990-07-19
PL253739A1 (en) 1986-03-11
JPH07250692A (ja) 1995-10-03
PL155410B1 (en) 1991-11-29
IE851321L (en) 1985-11-30
IL75318A (en) 1994-08-26
AU4320385A (en) 1985-12-05
IE930589L (en) 1985-11-30
SK278333B6 (en) 1996-11-06
YU47735B (sh) 1996-01-08
ES8802182A1 (es) 1988-04-16
FI93025B (fi) 1994-10-31
EP0509553A1 (en) 1992-10-21
FI852143A0 (fi) 1985-05-29
NO852173L (no) 1985-12-02
DK241385A (da) 1985-12-01
EP0164965A3 (en) 1988-04-06
DE3588225T2 (de) 2001-04-05
EP0164965A2 (en) 1985-12-18
JP2521703B2 (ja) 1996-08-07
IL75318A0 (en) 1985-09-29
CZ393085A3 (en) 1997-07-16
GR851317B (https=) 1985-11-25
FI852143L (fi) 1985-12-01

Similar Documents

Publication Publication Date Title
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
Lozier et al. Complete amino acid sequence of human plasma beta 2-glycoprotein I.
Duckworth et al. Purification of insulin-specific protease by affinity chromatography
Robey et al. Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity.
DE69112207D1 (en) "walk-through"-mutagenese.
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
AU590896B2 (en) Improved formulations for recombinant beta-interferon
KR880701288A (ko) M-csf의 제법
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
EP0134385A3 (en) A protein having cell growth stimulating action, composition thereof and method for producing the same
ATE121752T1 (de) Entfernung von protein a aus antikörper- präparationen.
Pickering et al. Adrenocorticotropin XXVII. On the presence of pig-tyre adrenocorticotropin in sheep pituitaries, and a simple method for the isolation of αs-adrenocorticotropin
CA1267497C (en) PROTEIN RECOVERY
KR890001581A (ko) 조직인자 억제제
FI101476B1 (fi) Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi
Church et al. Identification of two distinct species of procollagen synthesized by a clonal line of calf dermatosparactic cells
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
KR860002526A (ko) 단백질의 상호 분리 방법
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
GR3015689T3 (en) Process for the construction of an animal cell line for the production of human beta-interferon.
DE3151738C2 (https=)
Stathakis et al. Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains
GB9311454D0 (en) Pharmaceutical compositions
ATE119914T1 (de) Peptide, deren verwendung als immuno- suppressanten und verfahren zu deren herstellung.
DK0383599T3 (da) Protein-anticancermiddel